Kornimate/medical-research-clean huggingface dataset:
the yield of laryngeal ultrasound in the evaluation of stridor and dysphonia in children

Conditions: Stridor; Vocal Cord Paralysis

Summary: stridor is a respiratory noise caused by partial obstruction of the large airways at the level of the pharynx, larynx and/or trachea. the second most common cause of stridor is vocal cord paralysis. awake nasolaryngoscopyn (anl) is regarded as the gold standard for the diagnosis of laryngomalacia. however, anl has some drawbacks as it may cause discomfort for the patient and the laryngeal view may be obscured due to patient movement or anatomical variations. ultrasound (us) is a noninvasive, painless, radiation free, well tolerated imaging technique. evaluation of the dynamic characteristics of the glottis by us revealed perfect reliability in comparison to nasolryngoscopy suggesting that us can be useful in the assessment of laryngeal adduction. the investigator hypothesize that laryngeal us can be an accurate and reliable adjunct in the diagnosis of functional and anatomical causes of stridor and dysphonia in the pediatric population.


Eligibility criteria:
inclusion criteria: children aged 0-16 years referred for an awake nasolaryngoscopy for stridor or dysphonia at the pediatric otolaryngology unit at the tel aviv sourasky medical centre will undergo us of the larynx. exclusion criteria: * none

Keywords: stridor vocal cord paralysis (vcp) ultrasound (us)
sentinel lymph node biopsy in patients with breast cancer after neoadjuvant therapy

Conditions: Breast Cancer

Summary: the aim of this study is to create clear indications for sentinel lymph node biopsy (slnb) or axillary dissection (ad) in women with breast carcinoma after neoadjuvant therapy by studying the false negative rate of slnb.

the main object of the study is to evaluate, whether sentinel lymph node biopsy (slnb) at women with breast cancer after neoadjuvant therapy is a method with a high false-negative rate. patients will be classified into groups according to histological findings during slnb, clinical and ultrasonography (usg) findings in the axilla. the aim of this study is to create clear indications for slnb or axillary dissection (ad). in case of extension of slnb indications, there will be a decrease in morbidity after surgical therapy when compared to ad, which will mean a profit for the patients.

Eligibility criteria:
inclusion criteria: * diagnosis of breast carcinoma confirmed by biopsy * neoadjuvant therapy * examination of axillary lymph nodes clinically and by ultrasound * surgical therapy after neoadjuvant therapy exclusion criteria: * inflammatory breast carcinoma * incomplete neoadjuvant therapy * previous sentinel lymph node biopsy performed on the same side of the body * disagreement with participation in the study * other malignities influencing the treatment of breast carcinoma * distant metastases

Keywords: breast cancer neoadjuvant therapy sentinel lymph node biopsy axillary dissection
programmed flexor-extensor alternating electrical acupiont stimulation on limb functional reconstruction after stroke

Conditions: Stroke Sequelae; Movement Disorders

Summary: the purpose of this study is to study the effect mechanism of programmed flexor-extensor alternating electrical acupiont stimulation on upper limb functional reconstruction after stroke.

after being informed about the study and potential risks, all patients who meet the inclusion criteria, after signing the informed consent, will be randamized divided into two groups in a blind manner. the patients will undergo a 3-week treatment (6 days per week and 1 day for rest, a total of 18 days of treatment). those in the control group are treated with conventional flexor-extensor alternating electrical acupiont stimulation, and in the treatment group, programmed stimulation will be adopted (30 minutes, once a day). besides, data from healthy participants will be collected and processed for reference and control purposes.

Eligibility criteria:
inclusion criteria: * inclusion criteria for patients 1. meet the diagnostic criteria of stroke; 2. age: 35 \~75 years old, male and female; 3. course of disease: 2 weeks to 3 months after stroke, stable vital signs, basically normal cognitive function, can cooperate to complete the test; 4. manual muscle test (mmt) ≥2, modified ashworth (mas) of paralyzed upper limbs was graded ⅰ\~ⅱ; 5. bmi ≤28; 6. no serious heart, lung, kidney and other functional damage and serious underlying diseases, no pain in the affected side of the upper limb joint; 7. the informed consent was signed by the patient and/or his/her family members. note: patients who meet the above 7 criteria can be included in this study. * inclusion criteria for healthy subjects: 1. those who have been proved to be healthy by physical examination and have no organic lesions or obvious functional diseases; 2. age: 35 \~75 years old, male and female; 3. no cold, fever, cough, headache and other physical abnormalities during the test; 4. did not take any excitatory drugs in the past one month, no recent treatment related to experimental content; 5. no history of mental or nervous system; 6. the subject agrees and signs the informed consent. * exclusion criteria: 1. severe cognitive dysfunction, severe aphasia, can not cooperate with the whole treatment or testing process; 2. patients with serious primary diseases such as heart, lung, kidney, liver and endocrine system; 3. neurological or musculoskeletal diseases affecting functional recovery before onset; 4. cerebral stem stroke or bilateral stroke; 5. patients with severe anxiety, depression, affective disorders, schizophrenia and other serious mental disorders; 6. examination confirmed by brain tumor, brain trauma, brain parasitic diseases, metabolic disorders, rheumatic heart disease, coronary heart disease and other heart disease with atrial fibrillation caused by cerebral embolism; 7. patients with skin damage, infection or deformity at the treatment site.

Keywords: functional electrical stimulation stroke sequelae movement disorders
10 year registry of children (ages 2-17 years) with eczema that have used pimecrolimus

Conditions: Atopic Dermatitis

Summary: this study will examine the risk of systemic malignancies in pediatric patients with atopic dermatitis exposed to elidel 1% cream.

registry study to examine the risk of systemic malignancies in pediatric patients with atopic dermatitis exposed to elidel 1% cream.

Eligibility criteria:
inclusion criteria: * males and females * greater than or equal to 2 years and less than or equal to 17 years at enrollment * diagnosis of atopic dermatitis (confirmed by treating physician) * applied pimecrolimus cream 1 % 6 weeks out of past 24 weeks exclusion criteria: * past or present history of systemic malignancy, skin malignancy, or lymphoproliferative disease * past or present use of oral immunosuppressive therapy

Keywords: atopic dermatitis eczema pediatric pimecrolimus malignancy
efficacy and safety of dapagliflozin in children with proteinuric chronic kidney disease

Conditions: Proteinuria; Chronic Kidney Diseases

Summary: we aim to investigate the antiproteinuric effect of adding dapagliflozin to the standard of care in children with proteinuria.

blockers of renin angiotensin aldosterone system (raas) such as angiotensin converting enzyme inhibitors (acei) or angiotensin ii receptor blockers (arbs) are considered the standard of care in treatment of proteinuric chronic kidney disease. however, these agents lead to incomplete renal protection. the purpose of the study is to investigate the antiproteinuric effect of adding dapagliflozin to the standard of care in children with proteinuria. in this study, participants were randomly assigned (1:1) to receive acei+dapagliflozin (5mg or 10mg, based on body weight) or acei only once daily for 24 weeks. prespecified outcomes includes changes in 24-hr proteinuria, albumin, egfr (estimated glomerular filtration rate), blood pressure, body weight and so on.

Eligibility criteria:
inclusion criteria: * age 6 years to 18 years； * urinary protein excretion \> 200 mg in a 24-hr urine collection； * without any immunosuppressant medications such as corticosteroids, cnis and so on； * estimated gfr ≥ 60 ml/min/1.73m2（estimated with schwartz formula）； * no history of diabetes； * on stable doses of ace inhibitors or angiotensin receptor blockers (arbs) for \> 1 month； * willing to sign informed consent. exclusion criteria: * autosomal dominant polycystic kidney disease or autosomal recessive polycystic kidney disease, lupus nephritis, or anca-associated vasculitis; * blood pressure less than 5th percentile of the same gender, age, and height; * uncontrolled urinary tract infection at screening; * at risk for dehydration or volume depletion; * evidence of hepatic disease: an aspartate aminotransferase (ast) or alanine aminotransferase (alt) two times the upper limit of normal * history of organ transplantation, cancer, liver disease; * any medication, surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of medications including, but not limited to any of the following: 1. history of active inflammatory bowel disease within the last six months; 2. major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection; 3. gastro-intestinal ulcers and/or gastrointestinal or rectal bleeding within last six months; 4. pancreatic injury or pancreatitis within the last six months; * participation in another therapeutic trial with an investigational drug within 30 days prior to informed consent; * history of noncompliance to medical regimens or unwillingness to comply with the study protocol.

Keywords: angiotensin converting enzyme inhibitors sodium-glucose co-transporter 2 inhibitors dapagliflozin
effects of flavonoids on cognitive performance in healthy young adults

Conditions: Neurodegeneration

Summary: the purpose of this study is to investigate changes in cerebral blood flow, blood flavonoid levels, brain-derived neurotrophic factor, vascular reactivity and cognitive performance in young adults as a result of acute administration of a fruit-derived flavonoid-rich or flavonoid-poor drink.

there has recently been an increasing interest in the potential of flavonoids, plant derived compounds found in foods such as fruit and vegetables, to ameliorate age-related cognitive decline. research suggests that flavonoids improve memory and learning, possibly as a result of their anti-oxidant, anti-inflammatory and neuroprotective effects for example by increasing cerebral blood flow, protecting vulnerable neurons, enhancing existing neuronal function or by stimulating neuronal function. the research will initially involve a randomised cross-over human dietary intervention trial using two flavonoid-rich drinks (flavanone-rich and flavanone-poor) to investigate changes in cerebral blood flow in young adults (n=6; age range 18-30 years). changes in cognitive performance and measures of serum bdnf levels will then be investigated in a second randomised cross-over trial using the intervention drink showing the greatest effect on cerebral blood flow in young adults (n=24; age range 18-30 years) and using a range of sensitive tests of executive function. the study is designed to measure acute effects of types of flavonoid supplementation and, as well as the primary cognitive outcome, will assess flavonoid/metabolite and bdnf (brain-derived neurotrophic factor) levels in blood and changes in vascular reactivity.

Eligibility criteria:
inclusion criteria: * mmse between 26 and 30 * 18-30 years of age * native or good english speaker * normal bmi/body fat composition * no significant vision, hearing or language problems * able to consume the beverages exclusion criteria: * any form of disease/major mental illness/chronic fatigue syndrome * on medication for hypertension/elevated lipids/diabetes * on medication known to impact endothelial function * gall bladder/gastrointestinal abnormalities * sensitivity to orange or apple * high consumer of fruit, vegetables, fruit beverages * high consumer of caffeine or alcohol * consumer of illegal substances * vegetarian/vegan/other dieter/vigorous exerciser * use of antibiotics in the previous 8 weeks * consumer of dietary supplements

Keywords: flavonoid cognitive performance cognitive function executive function fmri cerebral blood flow acute
identification of barriers and facilitators of implementation of the out-of-hospital administration of the long- acting combination cabotegravir+rilpivirina.

Conditions: HIV-1-infection

Summary: the study will identify the barriers and facilitators of implementation of the out-of-hospital administration of cab+rpv la from the point of view of staff participating in the study.

this substudy will use a qualitative descriptive approach based on consolidated framework for implementation research (cfir). data will be collected using semi-structured interviews among hola staff participants until achieving data saturation. data will be analyzed using braun \& clarke\&#39;s thematic analysis method.

Eligibility criteria:
inclusion criteria: 1. participation throughout the hola study until the moment of conducting the interviews and direct involvement in the study procedures in a significant way. 2. homogeneous sample between the different roles participating in the study. 3. participants who agree to participate in the substudy and sign the informed consent. exclusion criteria: none

Keywords: barriers and facilitators interview long acting out-of-hospital by implementation cabotegravir + rilpivirine (cab+rpv) hiv-1
3f8/gm-csf immunotherapy plus 13-cis-retinoic acid for primary refractory neuroblastoma in bone marrow

Conditions: Neuroblastoma

Summary: the purpose of this study is to see find out what effects, good and/or bad, the combination of 3f8 and gm-csf has on the patient and the cancer.


Eligibility criteria:
inclusion criteria: * diagnosis of nb as defined by a) histopathology (confirmed by the mskcc department of pathology), or b) bm metastases or mibg-avid lesion(s) plus high urine catecholamine levels. * high-risk nb as defined by risk-related treatment guidelines1 and the international nb staging system,89 i.e., stage 4 with (any age) or without (\> or = to 18 months of age) mycn amplification or mycn-amplified stage 4s. * patients have primary refractory disease limited to bm, i.e., high-risk nb (defined above) resistant to standard therapy, as evidenced by incomplete response in bm, but no measurable mibg-avid soft tissue tumor assessable for response and no progressive disease. * signed informed consent indicating awareness of the investigational nature of this program. exclusion criteria: * creatinine \> 3.0 mg/dl * alt, ast and alkaline phosphatase \> 5.0 times the upper limit of normal * bilirubin \> 3.0 mg/dl * patients with grade 3 or higher toxicities (using the ctcae v 4.0) related to cardiac, neurological, pulmonary or gastrointestinal function as determined by physical exam. patients must have normal blood pressure for age. * progressive disease * history of allergy to mouse proteins. * active life-threatening infection. * human anti-mouse antibody (hama) titer \>1000 elisa units/ml. * inability to comply with protocol requirements.

Keywords: gm-csf mab 3f8 retinoic acid (cis-9 & 13) 09-161
predictive factors of recurrence of non functioning pituitary adenomas : a retrospective study of 220 patients in the reims university hospital, france

Conditions: Pituitary Adenomas

Summary: non functioning pituitary adenomas (nfpas) are the most common pituitary adenomas. their growth is usually slow and diagnosis is often made in the context of masse effect .the therapeutic alternatives are surgery and radiotherapy such as fractionated stereotactic radiotherapy. nowadays, there is no clinical or histological prognostic factor to allow an individualized follow-up and recurrence could happen 10 or 15 years after the first surgery. in this study, the investigators evaluate nfpas recurrence rate after surgery and try to find predictive factors of recurrence to personalized the follow-up of each patient.


Eligibility criteria:
inclusion criteria: * patients \>18 year-old * diagnosis of nfpas confirmed with hormonal and histological analysis * patients who underwent surgery in neurosurgery unit of the reims university hospital between 01/01/1991 and 31/12/2004 exclusion criteria: -
the impact of glycemic control on rheumatoid arthritis disease activity on diabetic patients

Conditions: Rheumatoid Arthritis (RA; Diabetes Mellitus

Summary: the incidence of dm is unclear in ra but most prior data suggest that dm or insulin resistance in ra has risen because of activation of the immune system and/or ra therapy . besides, ra causes joints to become stiff, swollen, and agonizing. as a result, the patient may not want to exercise or move. one study found that 42% of people with ra are not physically active. the aim of this study is to evaluate the glycemic status among ra patients with type 2 diabetes and its association with disease activity.

taking the potential link between dm and ra into consideration, detection and control of dm will significantly increase prolonged prognosis and therefore decrease the economic burden of ra patients and death rate. the aim of this research is to examine diabetic ra's glycemic status and to assess the relationship between ra and dm's clinical characteristics as well as the therapy response in ra patients with diagnosed dm. keeping an eye on glycemic control in ra patients could prevent metabolic and cardiovascular comorbidities in those susceptible patients.

Eligibility criteria:
inclusion criteria: * type 2 diabetic patients * rheumatoid arthritis patients exclusion criteria: * gestional diabetes * type 1 diabetic patients

Keywords: glycemic control
trigger point incidence after lumbar disc herniation surgery

Conditions: Trigger Point Pain, Myofascial

Summary: our purpose is to determine the incidence of trigger points in patients who remain in a fixed position for a long time during lumbar disc herniation surgery.

the 110 participants between 30-70 years are chosen from patients who had lumbar disc herniation surgery. the trigger points are determined by manually palpating quadratus lumborum, iliocostalis lumborum, gluteus maximus, gluteus minimus, gluteus medius, ve piriformis muscles before and after surgery. data will be recorded on the patient assessment file and transferred to the computer and analyzed. data analysis will be performed with spss.20.

Eligibility criteria:
inclusion criteria: * to be between 30-70 years * to have low back pain during minimum 6 weeks * to be voluntary participation for this study * to approve the informed consent form * to have the trigger point causing low back pain on muscles including quadratus lumborum, iliocostalis lumborum, gluteus maximus, gluteus minimus, gluteus medius, ve piriformis muscles. exclusion criteria: * to be diagnosed with spinal stenosis or spondylolisthesis * to have any skin problem affecting lower extremity evaluation * to have tumor on spinal region * to have rheumatological or any systemic problem that may interfere with trigger point diagnose
registry study of extracorporeal cardiopulmonary resuscitation (ecpr) in china

Conditions: Extracorporeal Membrane Oxygenation Complication; Cardiopulmonary Arrest

Summary: the data of patients undergo extracorporeal cardiopulmonary resuscitation (ecpr) will be collected and analyzed. this study will provide useful information about the indication, the start time and others to improve the outcome of ecpr.


Eligibility criteria:
inclusion criteria: * age \>=18y * cardiac arrested patients accept ecpr treatment exclusion criteria: * no
pharmacokinetics of bibr 277 in hypertensive patients

Conditions: Hypertension

Summary: the pharmacokinetic profile of bibr 277 single dose given in capsule form to hypertensives was evaluated. the results of the present study are to be used in the japanese population pharmacokinetics analysis


Eligibility criteria:
inclusion criteria: * age: \>=20 years * sex: either male or female * patient status: either inpatient or outpatient, provided that the patient was available for hospitalisation from the day before the trial medication administration until the morning of the day after administration * bp: sitting systolic and diastolic blood pressures (sbp and dbp) taken the day before administration should be \>= 150 mmhg and \>= 90 mmhg, respectively. patients undergoing treatment with other antihypertensives were not excluded provided the above criteria were satisfied. exclusion criteria: * malignant hypertension * renovascular hypertension * severe heart failure (nyha functional class iii - iv), unstable angina pectoris, or history of myocardial infarction (within 6 months of onset) * atrioventricular conduction disturbance (degree ii to iii), atrial fibrillation, or serious arrhythmia * symptoms of cerebrovascular disorder * serious hepatic dysfunction * renal function disorder (serum creatinine \>= 4.0 mg/dl) * known hypersensitivity to angiotensin ii receptor antagonists * hyperkalaemia (potassium \>= 5.5 milliequivalents per liter (meq/l)) * treatment with the other investigational drug within 6 months of initiation of the present study * pregnant, breast feeding, possibly pregnant or planning to become pregnant during this study * previous treatment with the trial medication of the present study * otherwise judged ineligible by the investigator